INVESTMENT FOCUS

The RMGP Biopharma Fund targets
innovative early stage Biopharma

In partnership with FutuRx, an Israel-based, globally focused drug development platform,
founded by Orbimed, Johnson&Johnson and Takeda.

alt-text

Early Stage

$90B

Early-stage exits in 2016,
60% of all biopharma exits.

An industry shift towards early-stage deals.

Driven by rising cost of drug development, big pharma is seeking innovative de-risked assets. As a result, recent years saw a steep increase in early-stage M&A and licensing deals.

alt-text

BioPharma

9.4%

CAGR of
biopharmaceuticals market

BioPharma remains a strong investment opportunity.

Aging population, increase in healthcare spending,
and advancements in biology,
make biopharma an attractive sector.

Israel based

alt-text

1300

Life science companies

Israel is an innovation Hub.

Israel is a leader in R&D spending and IP generation per capita, with a rapidly growing pipeline in a variety of healthcare segments.

alt-text

Leading academic and research facilities

alt-text

Drugs originating from Israel generate $41B in revenue

copaxone-logo

Global focus

Scroll to top